Understanding PV and Things You Should Know Learning that you have Polycythemia Vera (PV) often leads to questions about what the diagnosis means and what to expect over time. Because it is a chronic condition that requires ongoing management, learning how PV is monitored and treated can make the diagnosis feel less overwhelming and help […]
Medicare reforms have helped some patients, but MPN financial assistance programs remain essential for those struggling with the cost of blood cancer treatment by David Wallace The Patient Advocate Foundation (PAF), which recently completed a strategic merger with the PAN Foundation in March 2026 to form the nation’s most comprehensive nonprofit dedicated to helping patients […]
How To Choose Your MPN Specialist: A Resource Guide for Patients Introduction For patients diagnosed with myeloproliferative neoplasms (MPNs), choosing the right specialist is one of the most crucial decisions in their healthcare journey. These rare blood cancers require deep knowledge, experience, and a collaborative approach to treatment that not all hematologists possess. While any […]
ASH 2024: MPN Research Highlights with Dr. Angela Fleischman Discover the latest breakthroughs in Myeloproliferative Neoplasm (MPN) research from ASH 2024 with insights from MPN expert Dr. Angela Fleischman. This year’s conference unveiled progress in understanding and treating MPNs, including Polycythemia Vera (PV), Myelofibrosis (MF), and Essential Thrombocythemia (ET). In this interview, Dr. Fleischman discusses […]
by David Wallace 2024 Patients Are Asking, Episode 2 In this MPN expert interview, Dr. Gaby Hobbs shares her expertise on the various treatment options for Polycythemia Vera (PV). She explains first-line therapies, including phlebotomy, hydroxyurea, interferon (Besremi), Jakafi and highlights the importance of individualized treatment based on patient-specific factors. Watch the full interview to […]
by David Wallace 2024 Patients Are Asking, Episode 1 In our ongoing effort to provide the latest insights and resources for the MPN community, we’re excited to share an informative video on tailoring JAK inhibitor treatment strategies for myelofibrosis. Our interview with MPN expert, Dr. Lucia Masarova covers important aspects of JAK inhibitors, their role […]
by David Wallace ASH 2023 Highlights: Patients Are Asking, Episode 3 Discover the latest MPN research from the ASH 2023 conference with MPN expert, Dr. Lucia Masarova. We cover the latest clinical trials, breakthrough treatments, and innovative approaches to MPN blood cancers. Learn about combination treatments for myelofibrosis and updates on clinical trials for polycythemia […]
Optimizing MPN Patient Outcomes: The Holistic Approach by David Wallace Join us as we sit down with renowned MPN expert, Dr. Angela Fleischman, for an enlightening conversation about living optimally with Myeloproliferative Neoplasms. Dive deep into actionable strategies for managing myelofibrosis and discover tips to enhance your journey with MPNs. Your host, David Wallace, founder […]
by David Wallace Patients Are Asking – Episode 1 In this MPN specialist interview with Dr. Ghaith Abu-Zeinah, we learn what the term “disease modification” means. We discuss promising late-stage clinical trials and the importance of tracking your symptoms to discuss with your physician. David Wallace, PV Reporter, is your host and patient advocate. […]
Abstract Patients (pts) with polycythemia vera (PV) suffer from pruritus, night sweats, and other symptoms, as well as from thromboembolic complications and progression to post-PV myelofibrosis. Ruxolitinib (RUX) is approved for second-line therapy in high-risk PV pts with hydroxyurea intolerance or resistance. The RuxoBEAT trial (NCT02577926, registered on October 1, 2015, at clinicaltrials.gov) is a […]
Site by: Kaleidoscopic
